Estradiol/levonorgestrel transdermal - Labtec

Drug Profile

Estradiol/levonorgestrel transdermal - Labtec

Alternative Names: Estradiol + levonorgestrel transdermal - Labtec; Levonor TDS; Levonorgestrel + estradiol transdermal - Labtec; Levonorgestrel/estradiol transdermal - Labtec

Latest Information Update: 12 Nov 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Labtec
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 02 Jan 2007 Registered for Menopausal syndrome in the European Union under the mutual recognition procedure with Sweden as the reference member state (Transdermal)
  • 11 May 2006 This product is still under review for approval in the European Union
  • 31 Mar 2004 This product has been filed for approval within the European Union through the mutual recognition procedure; Sweden is acting as the reference member state
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top